{
    "title": "Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12480171/Genmab-Seagen-say-Tivdak-cervical-cancer-trial-met-overall-survival-endpoint.html",
    "date": "2023-09-04",
    "keywords": [
        "trial",
        "cancer",
        "tivdak",
        "seagen",
        "phase",
        "recurrent",
        "survival",
        "inc",
        "monday",
        "therapy",
        "endpoint",
        "brand",
        "name",
        "tisotumab",
        "conjugate",
        "data",
        "monitoring",
        "committee",
        "efficacy",
        "boundary",
        "analysis",
        "presentation",
        "congress",
        "benefit",
        "milestone",
        "treatment",
        "option",
        "officer",
        "roger",
        "innovatv",
        "randomized",
        "versus",
        "choice",
        "chemotherapy",
        "september",
        "food",
        "drug",
        "administration",
        "approval",
        "adult",
        "type",
        "progression",
        "pfizer",
        "process",
        "reporting",
        "vanaik",
        "bengaluru",
        "editing",
        "obrien",
        "cynthia",
        "osterman"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}